Skip to main content
. 2017 Jul 6;11(8):311–325. doi: 10.1177/1753465817717134

Figure 2.

Figure 2.

Changes in FEV1 and AQLQ over 52 weeks in patients receiving reslizumab or placebo in Study 3082 (A, C) and Study 3083 (B, D).36

AQLQ, asthma quality of life questionnaire; FEV1, forced expiratory volume in 1 s; LS, least-squares; *p < 0.05. p < 0.01 versus placebo. Reproduced with permission of Elsevier, from Castro and colleagues;36 permission conveyed through Copyright Clearance Center, Inc.